A Study to Evaluate Pharmacogenomics in the Medical Management of Native American Patients with Kidney Transplant

Overview

About this study

This study aims to understand the pharmacogenomics of Native American patients compared to Caucasians who are undergoing kidney transplant for treatment of kidney disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • Adult patients who are actively listed for a first or subsequent kidney transplant who are admitted to the hospital to undergo a kidney transplant.
  • An equal number of Native American patients and non-Hispanic Caucasians (race will be identified based on how the patient classified themselves in EPIC).

Exclusion Criteria:

  • Pregnant patients.
  • Mentally incapable of signing a consent form.
  • Patients awaiting combined organ transplant.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mira Keddis, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions